



October 15, 2018

Mr Luis Aguilar & Dr. Neil Yeston
Ethics & Compliance Committee - MiMedx
1775 West Oak Commons Ct. NE
Marietta, GA 30062

Dear Sirs,

OPEN LETTER: Request for investigation into perceived/potential conflict of interest – Re: MiMedx Inc.

On July 2, 2018 MiMedx announced the resignation of MiMedx CEO and Founder, Parker H. Petit, and the appointment of Mr. David Coles, a Managing Director of Alvarez & Marsal¹, as the company's interim CEO.

The appointment of Mr. Coles follows MiMedx's engagement of KPMG and King & Spalding, who we understand have been tasked, amongst other things, with conducting an independent internal investigation into MiMedx sales practices².

Viceroy understands that a key element of these internal investigations concerns MiMedx's conduct with the United States Department of Veteran's Affairs (DVA); specifically, the allegations of channel stuffing and the subsequent indictment of DVA physicians utilizing MiMedx products. These physicians are in the process of cooperating with the US Attorney General's case in relation to the charges alleged in the criminal filings including receiving bribes and inducements, and over-use of MiMedx product within the VA.

Viceroy Research has been made aware of links between other Alvarez & Marsal and a cohort of individuals allegedly exercising undue influence over the DVA, colloquially referred to as the "Mar-a-Lago Crowd".

Given the depth of investigations occurring at MiMedx relating to the company's conduct with the DVA, Viceroy believe the appointment of Alvarez & Marsal represents an irremediable conflict of interest to MiMedx's ongoing internal investigations, and to the investigations we understand are ongoing within the DVA and other federal regulatory entities.

We have addressed a separate letter to the Department of Justice and the DVA's ethics committee outlining what we believe is a serious conflict of interest and undue influence within the DVA of several parties. Further, we believe that it is irresponsible that this group, when exposed by journalists, was saved from a congressional hearing by longtime friend of former MiMedx CEO Petit, Senator Jonny Isakson, who has benefited greatly from donations from MiMedx and Petit.

Enclosed is a brief report detailing our investigation into this matter. A more comprehensive report will be published post VA OIG approval. The PCAOB and Investigators has stated that "When an auditor is confronted with multiple indicators of problematic revenue recognition ... he or she must get to the bottom of the relevant issues, including digging into management's representations." We stand ready to assist in this effort and sincerely appreciate your attention to this extremely important matter.

Yours faithfully

Fraser Perring

Viceroy Research

cc.

King & Spalding documents_intake@KSLAW.com

Alvarez & Marsal alvarezmarsal@alvarezandmarsal.com

Edmund Polubinski edmund.polubinski@davispolk.com

Ernst & Young – Andrew Brock andrew.brock@ey.com

¹ <https://www.alvarezandmarsal.com/our-people/david-coles>

² <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-postpones-release-its-fourth-quarter-and-fiscal-year-2017>



Attention: Whistleblowers

Viceroy encourage any parties with information pertaining to misconduct within MiMedx or any other entity to file a report with the appropriate regulatory body.

We also understand first-hand the retaliation whistleblowers sometimes face for championing these issues. Where possible, Viceroy is happy act as intermediaries in providing information to regulators and reporting information in the public interest in order to protect the identities of whistleblowers.

You can contact the Viceroy team via email on viceroyresearch@gmail.com.

About Viceroy

Viceroy Research are an investigative financial research group. As global markets become increasingly opaque and complex – and traditional gatekeepers and safeguards often compromised – investors and shareholders are at greater risk than ever of being misled or uninformed by public companies and their promoters and sponsors. Our mission is to sift fact from fiction and encourage greater management accountability through transparency in reporting and disclosure by public companies and overall improve the quality of global capital markets.

Important Disclaimer – Please read before continuing

This report has been prepared for educational purposes only and expresses our opinions. This report and any statements made in connection with it are the authors' opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.

To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stock covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented "as is," without warranty of any kind – whether express or implied.

In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using this report, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.

This document or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.

Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.

As of the publication date of this report, you should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.

The authors may continue transacting directly and/or indirectly in the securities of issuers covered on this report for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.



Marc Sherman – One of “The Shadow Rulers of the VA?”

On August 7, 2018 an article published by independent non-profit ProPublica³ titled “The Shadow Rulers of the VA” revealed the existence of an informal council influencing the development of VA policy⁴. The group was comprised of members of the Mar-a-Lago club in Florida:

- Bruce Moskowitz, a Palm Beach doctor;
- Ike Perlmutter, Chairman of Marvel Entertainment; and
- **Marc Sherman, Managing Director of Alvarez and Marsal**

ProPublica released emails detailing meetings between the trio and with former DVA Secretary David Shulkin⁵, which were made available through a Freedom Of Information Act (FOIA) request.

The Mar-a-Lago crowd appear to be involved in conference calls, VA decision/policy-making and receiving updates from Shulkin regarding DVA plans and regulations. The expose by ProPublica has been followed by two cases brought by external bodies to compel the VA to produce documentation requested under FOIA relating to these individuals⁶⁷

Note that *none of the individuals above* have any experience in the government or military: they are private citizens acting in an unofficial, voluntary consulting capacity.

We encourage you to read these emails to fully understand the extent of this relationship:

The last call I need to schedule is with (b) (6) ... This is a call about the VA Tech Transfer Office. (b) (6) is the most highly regarded authority on medical tech transfer and understands what is needed to fix the problem.

Tuesday (2/28) Noon to 1 pm EST

Participants will be – Ike Perlmutter, Dr. Bruce Moskowitz, Marc Sherman and (b) (6).

It will be great if Secy Shulkin can join the call.

Thank you,
(b) (6)

Figure 1 Perlmutter, Moskowitz, Sherman and Shulkin schedule call regarding VA Tech Transfer Office




Figure 2 Marc Sherman's profile on Alvarez & Marsal's website

³ <https://www.propublica.org/about/>

⁴ <https://www.propublica.org/article/ike-perlmutter-bruce-moskowitz-marc-sherman-shadow-rulers-of-the-va>

⁵ <https://www.propublica.org/datastore/dataset/the-mar-a-lago-crowd-documents>

⁶ Case 1:18-cv-01925 Votevets Action Fund v. United States Department Of Veterans Affairs.

⁷ Case 1:18-Cv-02346 Democracy Forward Foundation Plaintiff, V. United States Department Of Veterans Affairs



FOIA emails show Mr. Sherman was in regular communications with Mr Shulkin, the Secretary of the DVA at the likely time the VA OIG and US AG wer investigating MiMedx and Doctors for ‘inducements, bribes and overuse.’⁸ More concerning is the tone of communications: Shulkin’s tone toward the Mar-a-Lago Crowd is that of an employee to their superior.

Mr Sherman appeared to be the middle man in setting up calls between private enterprises and Mr Shulkin, and recommending inclusion of many private institutions in what appears to be preliminary policy planning meetings:

On Dec 6, 2017, at 11:17 AM, Marc Sherman <(b) (6)> wrote:

GREAT. He is ready to kick it off and is standing by for me to set up a call with you, David Hoyt, me and him to do so. Let me know several alternative times that work for the two of you for a call over the next week or two. I also mentioned about your having the inspections together with the Joint Commission and he liked that idea, AND he would love to get options from you for CIO and HR candidates.

On Wed, Dec 6, 2017 at 11:09 AM, (b) (6) wrote:

Mark,

How did your lunch go with the Secretary

(b) (6)

(b) (6) MD, FACS

CEO and Executive Medical Director

Figure 3 Marc Sherman setting meetings between DVA & the Miami Cancer Institute

From: (b) (6)
Sent: Tuesday, January 02, 2018 9:18 AM
To: (b) (6)
Cc: (b) (6)
Subject: Friday afternoon

Hi (b) (6) – Happy New Year once again. Friday afternoon’s session will be at MITRE in McLean. I am cc’ing (b) (6) for the exact address (they have a few different buildings and I don’t want to give you the wrong one). (b) (6)

We can be flexible around the Secretary’s calendar. I am guessing 3pm would be optimal but I will let you work that out with Jackie W. Ideally 90 minutes on the ground (but we will take 60). This is a pretty big meeting. Below are some more details.

All day Friday, MITRE will be convening a group of experts to weigh in on interoperability. At the end of the day, we are going to ask them to share what they are recommending directly to the Secretary. We will also invite DepSec (b) (6) Dr. (b) (6) (b) (6) and (b) (6) (in place of me, I will be out with back surgery). Below is the information I already sent to the Secretary with a few updates in red.

1) January 5 MITRE expert panel. MITRE has at least 7 experts coming in for a full day. If you are available, I have asked them to reserve 60-90 minutes at the end for the experts to brief you on their recommendations at the end of this day (I would include the 3 of you + (b) (7) + (b) (6)). This will be at MITRE in McLean.

- The 7 experts are (with a few others possible):
 - (b) (6)
 - (b) (6), CIO, Mayo Clinic
 - (b) (6), President, HMMS

⁸ Criminal Case No.: 6:18-481-Dcc United States Of America V. Donna Becker



- (b) (6), Principal, Leavitt Partners, LLC (recommended by (b) (6))
- (b) (6), MD, PhD, University of Washington (note: we are having conversations with him about coming on board full-time via IPA)
- (b) (6), MD, American College of Surgeons (recommended by Marc Sherman + (b) (6))
- (b) (6) MD, MPH, Boston Children's Hospital (was on the previous MITRE panel, also one of the experts invited to the White House interoperability summit hosted by (b) (6) and (b) (6))
- Dr. (b) (6), Massachusetts General Hospital (per suggestion of Bruce Moskowitz and Marc Sherman)
- Possibly Dr. (b) (6)
- MITRE will basically be asking them 3 questions.
 - If they were us writing a contract with Cerner, what would they want included?
 - What is their perspective on what off-the-shelf solutions or emerging technologies for which we need to build flexibility in the contract to include? This will be their chance to weigh in on some of the ideas that people reach out to you/I about.
 - What other big ideas do they have that we should consider incorporating into the contract (such as the ones that (b) (6) already sent us unsolicited)?
- In addition to the outside experts – I have asked MITRE to also invite (b) (6), (b) (6) from ONC, and someone from CMS (I am working with (b) (6) who is (b) (6) senior advisor) as well as (b) (6) and (b) (6) (b) (6) is our guy behind the Digital Veterans Platform). (b) (6) and (b) (6) will be there in listen-only mode.

(b) (6)
Acting CIO & Executive-in-Charge, Office of Information & Technology
Department of Veterans Affairs

Figures 4 & 5 MITRE meeting schedule and attendance list

Tissue tagging – Undue influence

Our greatest concern from a corporate governance standpoint is the involvement of the Mar-a-Lago crowd in the formation of VA policy on Tissue Tagging, an area of reported malfeasance at MiMedx.

In essence, Tissue Tagging is the assignation of the proper utilization code for Human Cell and Tissue Products (HCTPs). Former MiMedx employee Jennifer Scott alleged MiMedx purposely mis-tagged products used in its Surgical line as used in Wound Care.

command over and over, with nothing ever changing. It became obvious to the Regional Sales Directors that the misreporting of revenue benefitted the company by inflating Wound Care revenue numbers.

17. Since Wound Care is a multi-billion dollar market, and most importantly, Wound Care directly is reimbursed by insurance and Medicare and provides a financial incentive to healthcare providers to use the products, unlike products billed in relation to surgery (OR). This is particularly important to show “the Street” and potential investors that Defendant has strong Wound Care Division revenue.

Figure 6 Extract from Scott v. MiMedx⁹

The alleged motivation for this mis-tagging is twofold:

1. Wound care products are directly reimbursed by Medicare and insurance
2. Following on from above, financial markets evaluated MiMedx's performance using the growth of the wound care division.

⁹ Case 3:18-cv-01815-S



According to Scott's complaint, the mis-tagging was well known in the company and something of an open joke. Scott's complaint goes on to allege her improper termination was due in part to her voicing of her concerns to senior MiMedx personnel.

Plaintiff to discuss this and other issues with the Wound Care Division. On several occasions Plaintiff brought up the fact that revenue was being misreported due to tissue tagging discrepancies to both Tim O'Brien and Joe Longo. These types of conversations happened at least a dozen times. It was a regular topic on Surgical (SSO) conference calls as well amongst all the SSO Regional Directors, Tim O'Brien and Joe Longo.

14. It was so commonplace as a topic, that the SSO Sales Directors would joke about Wound Care Division getting the credit or revenue that it should not have openly on conference calls.

Figure 7 Extract from Scott v. MiMedx

Viceroy Research, Aurelius Value, Marc Cohodes, and several whistleblowers have raised concerns with MiMedx's tissue tagging procedures. What is concerning to Viceroy is the Mar-a-Lago crowd's apparent preliminary review on the DVA's tissue tagging procedures and new implementations.

Ok

Sent with Good (www.good.com)

From: Bruce Moskowitz
 Sent: Friday, February 02, 2018 2:58:45 PM
 To: DJS
 Subject: Re: [EXTERNAL] AATB Follow-up to January 19th VA Meeting

DJS – David Jonathon Shulkin

Should be part of (b) (5)

Sent from my iPhone

> On Feb 2, 2018, at 5:11 PM, DJS <vacodjs1@va.gov> wrote:
 >
 > Bruce - what do you think of this?
 >
 >
 >
 > Sent with Good (www.good.com)
 >
 >
 > From: (b) (6)
 > Sent: Friday, February 02, 2018 10:37:35 AM
 > To: Shulkin, David J., MD
 > Cc: Clancy, Carolyn; Hyduke, Barbara; Nechanicky, Penny L.; Christy, Phillip; Icardi, Michael S.; (b) (6) (SAC); (b) (6) @lifelinkfound.org
 > Subject: [EXTERNAL] AATB Follow-up to January 19th VA Meeting
 >
 > Secretary Shulkin:
 >
 > Please find attached a letter from the American Association of Tissue Banks (AATB) and the AATB Tissue Policy Group (TPG) to thank the Department of Veterans Affairs (VA) for a very productive meeting on January 19, 2018. We found the exchange of key information regarding biological implants (including human tissue products) very informative.

AATB and AATB TPG wish to partner with the DVA over new tissue tagging policy

Shulkin explicitly asking Moskowitz for his views on the tissue tagging partnership

Figure 8 Sec. Shulkin consults Mr. Moskowitz over possible VA tissue tracking policy

We find it particularly unusual, given the scope of services offered by the DVA and many opportunities to improve quality of care, that Tissue Tagging was chosen as a focus area by the Mar-a-Lago crowd. We believe the perceived involvement of Sherman in the DVA's policy guidance on tissue tagging represents an irremediable conflict of interest for both MiMedx and the DVA's ongoing investigations.



Ethics Response to ProPublica concerns

The revelations of the ProPublica article led to calls for a hearing regarding the level of influence and actions of this “**unofficial committee**” that included Bruce Moskowitz, a Palm Beach doctor; Ike Perlmutter, Chairman of Marvel Entertainment; and **Marc Sherman, Managing Director of Alvarez and Marsal**.

The petition was denied by Senator Jonny Isakson (R-GA) on the apparent basis that Shulkin was no longer the secretary of the DVA, having been fired due to the outcome of an ethics investigation¹⁰.

Isakson said the problem was largely solved after Wilkie was sworn in last month.

“I think we’re moving ahead,” he said. “Most of them are out of there.”

Isakson added that the three men worked around the committee but never affected the committee’s agenda.

Figure 9 Republicans Won’t Probe Influence of Trump Friends at Veterans Department¹¹

This is despite ProPublica FOIA documents showing that the Mar-a-Lago Crowd’s involvement has persisted post-Mr Shulkin’s termination, as they appear to be in regular communications regarding strategy with current Secretary of Veteran’s Affairs Robert Wilkie:

From: RLW
Sent: Monday, April 23, 2018 11:09 AM
To: (b) (6); COS-PMO; (b) (6) @aol.com; (b) (6) Bruce Moskowitz; Marc Sherman
Subject: RE: [EXTERNAL] From (b) (6) & Ike Perlmutter

I was honored to visit with you. No matter how long I am here, there is a (b) (5)

Thank you again for taking time to see me.

Very Respectfully,

Robert Wilkie

From: (b) (6)
Sent: Saturday, April 21, 2018 1:49:02 PM
To: RLW; COS-PMO; (b) (6) @aol.com; (b) (6); Bruce Moskowitz; Marc Sherman
Subject: [EXTERNAL] From (b) (6) & Ike Perlmutter

Hello all,

Ike and I believe we speak for all of us when we say our meeting was extremely productive. For the first time in 1 1/2 years we feel everyone is on the same page. Everybody “gets it.”

With all of you, led by Rob and Pete-- our Veterans cannot lose.

Again, please know we are available and want to help any possible way 24/7.

Thank you for an amazing meeting.

Warmest regards ... (b) (6) & Ike

Figure 10 Exchange between Wilkie, Moskowitz, Sherman & Perlmutter regarding Wilkie’s appointment as Secretary of VA

¹⁰ <https://www.theguardian.com/us-news/2018/apr/01/david-shulkin-veterans-affairs-secretary-says-he-was-fired>

¹¹ <https://www.rollcall.com/news/politics/republicans-downplay-influence-trump-friends-veterans>



- v. On Robert Wilkie's first day as then-acting VA Secretary, Mr. Sherman was waiting for Mr. Wilkie in his office.³⁵
- w. On April 2, 2018, the Mar-a-Lago Council held a 30-minute meeting with then-acting Secretary Wilkie.³⁶

Figure 11 Extract – *VoteVets v. United States Department of Veterans Affairs*¹²

Senator Isakson is a long-time friend of former MiMedx CEO Petit. The pair have known each other since 1967 according to Isakson himself. **Isakson publicly defended Petit against allegations of insider trading in 2012** and regularly appears in news media supporting Petit, claiming to have known him for 45 years:

On Wednesday, several people spoke out in support of Petit.

"I've known him for going on 45 years and I've never known a finer guy," U.S. Sen. Johnny Isakson said. "I'm confident he will be exonerated."

Figure 12 Petit, Atlanta business exec, accused of offering insider trade info¹³

Isakson said he doesn't know details of Petit's FDA problems but has heard from Petit over the years as a "constituent and a friend" and agrees with Petit that the FDA has left companies hanging in regulatory limbo.

"It thwarts the development and the stability of the marketplace," Isakson said of the process. "The FDA should make decisions."

Figure 13 "The Trump of Georgia": Biotech executive Parker Petit goes to Washington¹⁴

The lack of congressional hearing has not stopped public response from many veteran's advocacy groups including the VoteVets Action Fund¹⁵ who have begun legal proceedings against the DVA and Sec. Wilkie for failing to subject the Mar-a-Lago crowd to the appropriate regulations.

¹² Case 1:18-cv-01925-TJK

¹³ <https://www.ajc.com/business/petit-atlanta-business-exec-accused-offering-insider-trade-info/m58lPe7mQ0jud7blu9HoTJ/>

¹⁴ https://www.salon.com/2017/04/02/the-trump-of-georgia-biotech-executive-parker-petit-goes-to-washington_partner/

¹⁵ <http://www.votevets.org/about>



17. Among other things, the FACA requires: (1) before acting or meeting, an advisory committee must file a charter with the Administrator of the General Services Administration ("GSA") or the head of the agency that created the committee; (2) the make-up of the committee must "be fairly balanced in terms of the points of view represented and the functions to be performed"; (3) the charter must contain appropriate provisions to "assure that the advice and

6

Case 1:18-cv-01925-TJK Document 1 Filed 08/16/18 Page 7 of 32

recommendations of the advisory committee will not be inappropriately influenced by the appointing authority or by any special interest, but will instead be the result of the advisory committee's independent judgment"; (4) all meetings must be open to the public; (5) notice of each meeting must be published in the Federal Register; (6) all interested persons must be allowed to attend, appear before, or file statements with the advisory committee; (7) all records, reports, transcripts, minutes, appendices, working papers, drafts, studies, agendas, and other documents made available to or prepared for or by the advisory committee must be available to the public, and (8) detailed minutes of each meeting must be kept. *Id.* §§ 5(b)(2)-(3), 5(c), 9(c), 10(a)(1)-(3), 10(b)-(c).

Figure 14

We fully encourage you to read the FOIA responses in full to understand the scope of the Mar-a-Lago crowd's influence. The full repository of FOIA responses regarding the Mar-a-Lago crowd are available at:

<https://www.propublica.org/datastore/dataset/the-mar-a-lago-crowd-documents>

Viceroy would like to further commend ProPublica on the depth of their due diligence and journalistic efforts in this matter.



Request for action

The Mar-a-Lago crowd are alleged to be influencing DVA policy development and implementation without any accountability, oversight or control. It includes a managing director of the firm now providing executive capacity services to MiMedx, who are embroiled in an ongoing internal investigation relating to revenue recognition practices at DVA centers. We believe there is a present or perceived conflict of interest in this scenario which is irremediable, both for the DVA's apparent ongoing investigations into MiMedx & for MiMedx's own internal investigations.

Given the concerns and apparent connections between Alvarez & Marsal and the DVA, we request the following:

1. Alvarez & Marsal to immediately make available its internal conflict check (and any conflicts raised) preceding Mr. Coles' appointment as CEO of MiMedx to investors and addressed parties. This check is performed at professional services firms prior to a client engagement. The conflict checks consider if the engagement will impair existing engagements, or if the engagement cannot be completed to an acceptable level of objectivity due to pre-existing relationships.
2. MiMedx to disclose whether or not the firm, or any of its staff, were previously engaged with Alvarez & Marsal or *any* associated related parties, including discussions with the DVA or other Government Agencies that are now investigating MiMedx.
3. MiMedx's to reveal specifically whether or not Alvarez & Marsal, its consultants, related parties or staff were engaged with the independent investigation announced December 27, 2016¹⁶, wherein the former CEO of MiMedx claimed exonerated the board and company on the basis of the said investigation.
4. MiMedx's independent investigators and audit committee to disclose if MiMedx or any related or third parties had any relationship with Mr. Marc Sherman. If so, please disclose the extent of the relationship.
 - a. If Alvarez & Marsal were not involved in the previous internal investigation, MiMedx should immediately release the details of the revenue recognition expert that 'exonerated' both the audit committee and board as a whole.
5. To disclose whether MiMedx's termination of Directors for cause was because of indictments that Alvarez & Marsal subordinates are now investigating to assess any risks and restructuring requirements.
6. To disclose Alvarez & Marsal's involvement in the DVA OIG and Dept of Defense investigations, including any calls, messages, emails between Mr Marc Sherman & those departments since A&M's appointment. These have also been FOIA requested.
7. We request MiMedx's to disclose Alvarez & Marsal's involvement, if any, in assisting with the DVA investigation/s announced in MiMedx's press release dated September 7, 2017.

We are led to believe there is a formal investigation by the Office of the Inspector General of the VA relating to the conduct of Mr. Marc Sherman of Alvarez & Marsal and his associates.

We have addressed a separate letter to the Department of Justice and the DVA's ethics committee outlining what we believe is an irremediable conflict of interest through Mr. Sherman's undue influence within the DVA. Further, we believe that it is irresponsible that this group, when outed, was saved from a congressional hearing by a longtime friend of former MiMedx CEO Petit, Senator Jonny Isakson, who has benefited greatly from MiMedx and Petit donations.

¹⁶ <https://www.prnewswire.com/news-releases/mimedx-announces-preliminary-investigation-findings-300383623.html>



Annexure

Timeline of events at MiMedx

Following the announcement of the most recent investigation into the irregularities at MiMedx, the company announced the following events:

Date	Event
September 7, 2017	MiMedx announce they had provided information to the Department of Veteran's Affairs in relation to an investigation, of which they claim they were not a target.
May 8, 2018	Three VA employees are indicted for receiving bribes, inducements and undisclosed gifts from MiMedx and caused the excessive use of MiMedx products. ¹⁷
May 10, 2018	MiMedx Comments on Matters Related to Former VA Employees ¹⁸
June 6, 2018	Michael J. Senken, the Company's Chief Financial Officer and John E. Cranston, Vice President, Corporate Controller and Treasurer. Edward J. Borkowski appointed as Interim Chief Financial Officer
June 7, 2018	MiMedx announces that it will restate Certain Historical Financial Statements relating to the fiscal years ended 2012 to 2016 and interim periods of 2017. Communications regarding Q4 2017 and Q1 2018 should no longer be relied upon ¹⁹ .
July 2, 2018	MiMedx Announces Leadership Changes and Corporate Actions ²⁰ - Parker H. Petit resigns as Chairman and Chief Executive Officer and Bill Taylor resigns as President and Chief Operating Officer. Charles Evans appointed Chairman of the Board and David J. Coles of Alvarez & Marsal appointed Interim Chief Executive Officer. Terms & Conditions of Engagement with Alvarez & Marsal including remuneration for David Coles ²¹ . SEC Appointment Terms for David Coles ²² .
July 18, 2018	MiMedx Appoints Mark Graves Chief Compliance Officer to Strengthen Corporate Compliance Practices ²³ .
July 26, 2018	MiMedx Announces Receipt of Nasdaq Letter ²⁴ .
August 13, 2018	MiMedx Announces Nasdaq Listing Extension and Hearing Date ²⁵ .

¹⁷ South Carolina District Court Case No. 6:18-cr-00481-DCC USA v. Becker et al

¹⁸ <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-comments-matters-related-former-va-employees>

¹⁹ <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-estate-certain-historical-financial-statements>

²⁰ <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-announces-leadership-changes-and-corporate-actions>

²¹ <https://www.sec.gov/Archives/edgar/data/1376339/000119312518215806/d398294dex101.htm>

²² <https://www.sec.gov/Archives/edgar/data/1376339/000119312518215806/d398294d8ka.htm>

²³ <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-appoints-mark-graves-chief-compliance-officer-strengthen>

²⁴ <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-announces-receipt-nasdaq-letter>

²⁵ <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-announces-nasdaq-listing-extension-and-hearing-date>



August 15, 2018	MiMedx Provides Additional Information and Context to Wall Street Journal Article ²⁶ .
September 20, 2018	<p>MiMedx Provides Update on Previously Announced Senior Executive Separations²⁷.</p> <p>Board and Compensation Committee Determine That Separations Be Treated as "For Cause" Terminations Based on Information from Audit Committee's Ongoing Independent Investigation.</p> <p>Parker H. Petit Resigns as Member of MiMedx Board, Effective Immediately.</p> <p>MiMedx Announces Nasdaq Listing Extension²⁸</p>

²⁶ <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-provides-additional-information-and-context-wall-street>

²⁷ <https://mimedx.gcs-web.com/news-releases/news-release-details/mimedx-provides-update-previously-announced-senior-executive>

²⁸ <https://www.prnewswire.com/news-releases/mimedx-announces-nasdaq-listing-extension-300716519.html>